Table 1 Baseline characteristics of patients who did and did not receive therapy from an implantable cardioverter‐defibrillator (ICD).
| Characteristic | ICD therapy (n = 63) | No ICD therapy (n = 282) | p Value |
|---|---|---|---|
| Age (years) | 61 (13) | 64 (13) | 0.22 |
| Men | 54 (86%) | 234 (83%) | 0.72 |
| Primary prevention | 34 (54%) | 147 (52%) | 0.68 |
| History of CHF | 48 (76%) | 226 (80%) | 0.57 |
| CAD | 40 (63%) | 206 (73%) | 0.19 |
| Dilated CM | 14 (22%) | 45 (16%) | 0.14 |
| Valvar/other CM | 9 (14%) | 31 (11%) | 0.29 |
| NYHA class | |||
| I | 15 (24%) | 60 (21%) | 0.12 |
| II | 20 (32%) | 131 (46%) | |
| III | 24 (38%) | 83 (29%) | |
| IV | 4 (6%) | 8 (3%) | |
| LVEF (%) | 23 (11) | 30 (13) | 0.048* |
| β Blocker | 47 (75%) | 197 (70%) | 0.49 |
| Amiodarone | 13 (21%) | 114 (40%) | 0.033* |
| Other antiarrhythmic | 11 (17%) | 28 (10%) | 0.16 |
| ACE inhibitor | 38 (60%) | 183 (65%) | 0.58 |
| Statin | 29 (46%) | 147 (52%) | 0.71 |
| Creatinine (μmol/l) | 124 (71) | 115 (80) | 0.65 |
| BNP (ng/l)† | 573 (205–824) | 243 (103–518) | 0.0003* |
| CRP (mg/l)† | 2.2 (0.35–8.4) | 1.75 (0.47–4.4) | 0.57 |
Data are mean (SD), number (%), or median (interquartile range).
*Significant difference.
ACE, angiotensin converting enzyme; BNP, B‐type natriuretic peptide; CAD, coronary artery disease; CHF, congestive heart failure; CM, cardiomyopathy; CRP, C reactive protein; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.